Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomalidomide - Celgene Corporation

X
Drug Profile

Pomalidomide - Celgene Corporation

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Phthalimides; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 6 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Multiple myeloma; Kaposi's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Kaposi's sarcoma; Multiple myeloma
  • Phase III Myelofibrosis
  • Phase II Brain cancer; Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • No development reported Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 10 Jan 2024 Janssen terminates a phase II trial in Multiple-myeloma in (Combination therapy, Second-line or greater therapy) in USA due to low accrual (NCT04700176)
  • 01 Nov 2023 Celgene terminates a phase II trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (PO) due to lack of enrollment (NCT02188368)
  • 14 Sep 2023 Celgene completes a phase II trial in Brain cancer (In adolescents, In children, In infants, Monotherapy, Recurrent, Second-line therapy or greater, In adults) in USA, France, Spain, United Kingdom and Italy (PO) (NCT03257631) (EudraCT2016-002903-25)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top